Navigation Links
Verenium Announces Changes in Senior Management
Date:2/25/2011

SAN DIEGO, Feb. 25, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced a series of changes within its senior management team to take effect March 31:

  • Carlos Riva, currently Director, President and Chief Executive Officer, will be retiring from his position at the Company.  He will continue to be available to the Company as a consultant for a period of time.
  • James Levine, currently Executive Vice President and Chief Financial Officer, will be promoted to President and Chief Executive Officer, succeeding Carlos Riva.  He will also be elected to the Company's Board of Directors.
  • Jeffrey Black, currently Senior Vice President and Chief Accounting Officer, will be promoted to Chief Financial Officer.  He will continue to report to Levine.
  • Janet Roemer will continue as Chief Operating Officer and will report to Levine.

  • "This is an exciting time for Verenium and I am very pleased to have the opportunity to continue to partner with Janet, Jeff and the rest of our team as we focus on realizing Verenium's vision of building the next leading industrial enzymes company," said James Levine, President and Chief Executive Officer Designate of Verenium.  "On behalf of the Company and our Board of Directors, I'd also like to recognize the many contributions Carlos made in his time here and wish him well with his future plans."

    About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

    Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contact:Kelly LindenboomVice President, Corporate Communications617-674-5335kelly.lindenboom@verenium.com
    '/>"/>

    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Verenium Announces 2010 Business Update and Outlook for 2011
    2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
    9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
    10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
    (Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
    (Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
    Breaking Medicine Technology:
    (Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
    (Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
    Breaking Medicine News(10 mins):